Report Scope: Several significant developments have aided and accelerated the growth of markets in biotechnology, in the period of review.Notable recent advancements in biotechnology are CRISPR, Spheroids for drug development, Quantitative Cell Based Assay using high content analysis platform and Luciferase based high-throughput screening assay.
Such technologies assure the wide adoption of cell line technologies for drug development, simplify the gene editing process making it cost-effective.
Companies operating in cell line market are investing huge amount in setting up manufacturing units with advanced state of art facility and expanded production facilities. At the same time, the genetic sequencing technology is advancing at a great pace especially in the healthcare sector in diagnosis of various cancers.
Gene therapy technology has opened new avenues which places emphasis on curing disease that do not have an effective therapeutic availability.Johnson & Johnson, together with the University of Pennsylvania, is developing a third-generation AAV-based gene therapy for Alzheimer’s disease.
The goal is to use AAV viral delivery to initiate the expression of therapeutic anti-Alzheimer’s antibodies in the brain.Novartis launched Zolgensma for the treatment of spinal muscular atrophy.
The research represents a novel way to get biologics into the brain to treat Alzheimer’s disease and other neurological diseases. This is expected to pave way for further innovations in AAV-based gene therapy.
The sector continuously faces some challenges related to marketing, paying for innovation, pricing pressures from the government organizations.
Paying for development costs is always most critical part for the manufacturers.In 2019, gene therapies and many cell biology technologies are developed to address the needs of some important diseases and proven to be effective.
However, this comes for a high cost.For example, Zolgensma, a viral vector based gene therapy for the treatment of spinal muscular atrophy costs around $5 million.
It is important to figure out how to pay for the innovation which is quite challenging.
The pricing and paying for getting the products to market are important challenges.The innovation may take several years from clinical trial phase to get launched in the market.
The investors may be disappointed if the company doesn’t show expected profits and loses the hope while stock prices fall. This means that companies must carefully manage expectations and maintain balance.
Our reports have been used by over 10K customers, including:
“Sialorrhoea – Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Sialorrhoea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule...
The market for cell culture is driven by factors such as rising demand for vaccines, artificial organs and biopharmaceuticals, and growing focus on personalized medicine. Immunization is the most valuable and cost-effective intervention that delivers better health as well as social and economic benefits. Annually, around 2 to 3 million...
INTRODUCTION Over the years, advances in cell biology and pharmacology have led to the development of a variety of advanced biologics, which experts believe, possess the potential to address several unmet needs associated with the treatment of different types of diseases. Currently, there are more than 1,000 cell and gene...
The North America bioreactors market is expected to reach US$ 2,102.75 Mn by 2027 from US$ 1,188.50 Mn in 2019. The market is estimated to grow at a CAGR of 7.5% during 2020-2027.The bioreactorsmarketis growing primarily due to the increasing adoption of single-use bioreactors and rising demand of bioreactors by biopharmaceutical and biotechnology...
The Asia Pacific bioreactors market is expected to reach US$ 994.52 Mn by 2027 from US$ 544.51 Mn in 2019. The market is estimated to grow at a CAGR of 7.9% from 2020 to 2027.The growth of the marketin this region is primarily attributed to the escalating demand for bioreactors and rising number of market players focusing on expanding their...
The Europe bioreactors market is expected to reach US$ 1,512.45 Mn by 2027 from US$ 885.26 Mn in 2019. The market is estimated to grow at a CAGR of 7.0% from 2020 to 2027.The growth of the Europe bioreactorsmarketis primarily attributed to the rapidly growing biopharmaceutical and biotechnology industriesand increasing adoption of single-use...
Nanopharmaceuticals - Thematic Research
Nanomedicine is the application of nanotechnology for the diagnosis, prevention, and treatment of disease.This report will focus on the use of nanomedicines for drug delivery and therapeutic purposes, which are often referred to as nanopharmaceuticals,...
This study covers the world outlook for biologics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks...
269 pages •
By Future Market Insight Global & Consulting Pvt Ltd
• Apr 2019
A recent market study published by the company ’Neurovascular Guidewires Market: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028’, consists of an inclusive assessment of the most important market dynamics on Cytomegalovirus with assessed medications. The company has done some direct research on the principle structure...
Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2) - Pipeline Review, H2 2018 Summary Granulocyte Macrophage Colony Stimulating Factor (GMCSF or Colony Stimulating Factor or CSF or Molgramostin or Sargramostim or CSF2)...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.